1-800-567-8911 or
604-682-5050
(Telephone interpreting in over 150 languages available)
Liraglutide + Insulin Degludec
Trade Name:
Xultophy
Manufacturer/Distributor:
Novo Nordisk
Classification:
Incretin mimetic + insulin
ATC Class:
A10AE56 - insulin degludec + liraglutide
Status:
active
Notice of Compliance (yyyy/mm/dd):
2018/04/11
Date Marketed in Canada (yyyy/mm/dd):
2018/06/06
Presentation:
Injection: per 1 mL: insulin degludec 100 IU, liraglutide 3.6 mg. DIN: 02474875
Comments:
This combination product is indicated as an adjunct to lifestyle modifications, for the once-daily treatment of adults with type 2 diabetes mellitus to improve glycemic control in combination with metformin, with or without sulfonylurea, when these combined with basal insulin (less than 50 units daily) or liraglutide (less than or equal to 1.8 mg daily), do not provide adequate glycemic control.
Back to:
Drug Product Listings 
